



SPARC/Sec/SE/2025-26/09

May 19, 2026

National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai – 400 051.

BSE Limited,
Market Operations Dept.
P. J. Towers,
Dalal Street,
Mumbai - 400 001.

Scrip Symbol: SPARC

Scrip Code: 532872

Dear Sir/Madam,

Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that our licensing partner Ocuvox Therapeutics Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility. The FDA did not raise any other issues with the PDP-716 NDA.

The above information is being submitted for your information and dissemination.

For **Sun Pharma Advanced Research Company Ltd.**

Kajal Damania
Company Secretary and Compliance Officer

Encl: As above